In The Hot Seat: Bristol Defends IO Position Amid Sliding Stock And Forecasts
Bristol's stock price dipped after the AACR meeting, where pivotal lung cancer data for Opdivo/Yervoy disappointed relative to Merck's Keytruda/chemo combo, but Bristol still has many immuno-oncology irons in the fire in other indications and expressed confidence in its strategy.
You may also be interested in...
Cancer immunotherapy is once again set to dominate the upcoming American Society of Clinical Oncology annual meeting, with a continuing showdown for PD-1 inhibitors in lung cancer, a CAR-T battle, and disappointments for new IO classes.
In the US there are more new starts on Keytruda than any other immunotherapy, Merck says in first-quarter earnings report.
Novel oral anticoagulant Eliquis (apixaban) brought in $1.5bn in the first quarter and is set to overtake warfarin later this year. But Bristol remains on the defense on IO after a disappointing AACR.